challeng compani coverag tie gener
opioid litig drug price aggreg base
univers spec pharma perform line drg
meaning under-perform
compani exposur gener opioid
perform materi wors averag
look overal macro headwind
debat elect year believ broad drug price overhaul
low probabl gener sale trend appear stabil
see sever key overarch theme group gener
stabil teva depend new launch opioid
price fix litig on-going visibl challeng
global settlement brand spec pharma stori product launch
attract pipelin outperform make stock pick
scale acquisit like given still lever balanc sheet
top idea recent filler acquisit highli
synergist slew catalyst upcom includ bla
accept late-januari sever data readout throughout
year aesthet therapeut indic bla approv
decis upsid option biosimilar opt-in april
potenti sale discuss competitor
report compani indic us privat equiti interest
space well primaten launch progress well
see sever pipelin catalyst drive valu near-term trade
like share potenti favor rule narcan
patent litig insid separ ebs/teva note
rate chang downgrad equal weight see
limit upsid potenti deal term expect transact
close bhc upgrad equal weight l/intern
organ growth continu low mid singl digit aid
sihi daili lumifi launch ortho derm begin grow
owe bryhali/duobrii launch slow howev
off-set potenti competit threat xifaxan sandoz cosmo
mix signific sale trend debt level recent
proprietari work includ report bhc physician survey
key product launch patent consult view narcan
ebs/teva xifaxan bhc patent case consult
view likelihood drug price legisl
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani cover
research report result investor awar firm may
conflict interest could affect object report
investor consid report singl factor make
drug price view broad overhaul drug price elect year unlik
occur return investor healthcar equiti mix volatil past six
 presidenti elect drug price legisl like hot topic candid elect
uncertainti creat headlin risk begin presid trump push
amend medicar pay drug priorit support grassley-wyden
packag understand lack widespread support given far apart congress
issu base convers consult see broad overhaul unlik
recogn neg drug price headlin may norm particularli presidenti
elect heat favor brand product launch pipelin stori win
note antipsychot protect class medicar
gener opioid outlook gener look stabil sale declin less
neg industri view gener recoveri predic new product
launch complex gener uptak slow advair copaxon sever product
delay opioid risk remain teva lesser extent visibl
resolut challeng despit improv investor sentiment around potenti opioid
resolut continu exercis caution name look better visibl get
tabl content
review tape
leverag outlook
catalyst
review tape
specialti pharmaceut index includ specialti brand gener compani
increas yoy line drg index meaning under-perform broader
market also significantli lag etf xbi increas
revers past three year neg return headlin number look better much
underli secur perform specialti gener index approxim
see exhibit name gener speak also among leverag name
spec pharma univers part variou litig suit
exhibit histor spec pharma perform vs relev indic absolut rel
factset secur llc
specialti pharma-brand index increas driven bhc among other outperform
 increas spec gener index meaning under-perform per exhibit
exhibit perform specialti brand specialti gener
note spec gener includ rdi teva rest spec pharma index includ
factset secur llc
pharma biotech pharma vs pharma vs drg stock perform jan pharmaspec genericspec brandgener meaningfullyunderperform spec brand pharma ralli outlook
specialti pharma plagu gener industri challeng opioid price fix litig
fear drug price regul elev debt level sentiment notabl improv start late last
year view particularli relat gener stock hope manag global settlement
opioid overal macro headwind dramat differ litig on-going gener
trend drug price like headlin risk elect uncertainti expect
broad drug price overhaul gener stabil growth like depend new
launch mani compani face opioid price fix litig on-going
suffici visibl amount structur time overhang lift
focus brand compani undergo product launch strong pipelin best
idea revanc amphastar
expect drug price remain popular debat item year presidenti elect
may sourc headlin risk investor return investor healthcar equiti
mix volatil past six presidenti elect exclud given sever econom
contract three past five elect produc posit return two
recent neg given presid trump democrat presidenti candid congress
focu drug price reform return may even volatil pay attent
winner democrat presidenti nomin his/her stanc pharmaceut
exhibit drg total return presidenti elect
factset secur llc
outsid elect focus two bill congress senat prescript drug price
reduct act -- sen grassley sen wyden see hous lower drug
new act -- sen cummings/pallon see
begin trump administr initi push chang medicar pay
drug focu peg medicar drug cost price intend
lower out-of-pocket expens review medicar coverag breakdown
part hospit coverag includ inpati visit special nurs facil hospic
part medic coverag includ doctor clinic lab servic outpati prevent care
surgic fee suppli
part medicar advantag combin part
part coverag prescript drug
trump administr propos legisl would affect part materi recent presid
trump walk back direct negoti drug price signal support grassley-wyden
bill includ modifi part program lower spend beneficiari out-of-pocket cost hh
secretari also indic need provid transpar rebat remov would
dramat impact drug price note rebat day number
go take action could run risk senior premium go
meanwhil congress note previous two bill would requir govern negoti brand
name drug price without current competit brand name drug
dec reuter report sever larg pharmaceut compani gsk etc plan
rais list price drug consist industri histor practic annual price
increas suggest industri concern chang
spoke consult likelihood legisl drug price
consult expect anyth transform year drug price
 pass hous expect clear pathway dead arriv passag
senat support trump administr
grassley/wyden bill real support republican though believ presid
trump put full weight administr behind howev note true swing
variabl if/when presid trump decid senat bill includ part
inflationari cap could problemat industri
consult spoken mitch mcconnel make action drug price
clear consensu republican current divid
peg chang bill move forward watch may
fund extens sever health care program expir may vehicl address
surpris medic bill prescript drug cost
view sure issu go away particularli throughout presidenti
debat headlin risk need mitig particularli howev
see broad overhaul like occur year
gener equiti challeng past sever year owe materi neg
price environ result signific payer consolid increas competit higher
fda approv opioid price fix litig highlight gener spec
pharma index declin approxim begin level
sentiment improv group index perform teva materi better
less continu year attribut newsflow potenti global
settlement opioid stabil gener trend view mani issu
challeng stock continu potenti beyond multipl overhang
opioid price fix litig remain open issu key risk opioid teva
put forward framework state pennsylvania tennesse north
carolina texa howev broad interest deal includ mdl plaintiff attorney
appear limit earli novemb teva ceo kare schultz indic litig could
end newsflow sinc limit industri meet sf
earli januari mr schultz note follow attorney gener us state repres
four state work still on-going turn framework actual settlement
cautious optimist work way posit way kind
deadlin come would advantag everybodi get actual settlement
done next state trial trial new york mid-march like said
cautious optimist find way get actual sign done remain
seen number includ ny ohio publicli state would
agre teva framework could function rel small cash compon
view meanwhil sever case proceed trial state level accord
judg jerri garguilo suffolk counti ny suprem court set trial date januari
opioid claim sever manufactur teva name suit howev
understand case push back march
separ number gener drug manufactur involv litig price fix
novemb bloomberg report gener manufactur discuss
justic depart resolv claim time potenti deal unclear
expect issu near-term overhang opioid litig bigger issu
teva vs view
 gener trend stabil delay approv slow uptak complex
gener key issu use iqvia data gener gross sale growth trend
point stabil environ sale yoy novemb vs averag monthli
declin exclud discount rebat think direct trend
exhibit total gener industri yoy sale growth
iqvia secur llc
teva novemb gener sale yoy compar averag sale declin
exhibit teva gener absolut sale yoy chang
iqvia secur llc
look teva ytd sale na gener sale improv year
flat earn call teva ceo kare schultz call
gener price satisfi stabil goe hand hand overal
stabil price environ north america europ gener addit
industri meet januari teva ceo note strong futur way see
tradit gener biosimilar marketplac price stabil debt
spiral bottom got ignit fda approv anda indian chines player
get marketplac stabil stabl supply-demand situat
work benefit patient manufactur
sale grown north america due new launch expens margin
agre gener trend begun stabil outlook view larg
depend new launch key product commodit face annual declin new launch
requir off-set light mani new launch delay exampl seen
signific delay g-copaxon rdi g-proair g-nuvar teva g-restati
teva recal also encount signific delay g-advair eventu gain approv
would also point approv complex gener necessarili equat meaning
penetr outset instanc accord iqvia data launch gadvair wixela
march initi achiev approxim weekli script share howev sinc time wixela
share climb addit week end
exhibit wixela gadvair market share week
iqvia secur llc
companyproducttarget datecommentarydr disclos earn calldr disclos earn approv dec dec approv dec jan launch call day launch launch market share specialti pharmaceut outlook
similarli copaxon market anoth complex gener gain share
remain market share launch late despit significantli cheaper price
point product part may due launch execut also emblemat
industri
iqvia secur llc
longer term biosimilar could meaning opportun exposur current
coverag though teva also launch sever biosimilar howev still earli day see
larg contributor gener compani depend adopt competit
launch neulasta biosimilar fulphila launch herceptin biosimilar similarli teva
launch rituxan biosimilar plan launch herceptin biosimilar late
leverag outlook
spec pharma coverag univers continu high leverag defin net debt-to-ttm ebitda
averag exclud compani current profit select compani
larg cash balanc debt comparison purpos bhc highest leverag
group approxim pro forma recent debt rais litig ex bhc gener
compani continu among highest leverag name coverag owe past ill-tim
acquisit declin ebitda
exhibit net leverag coverag univers
note bhc pro forma recent debt rais wfse ebitda
saw sever merger spec pharma compani reevalu long-term prospect
process acquir allergan mylan-upjohn merg spun cyclerion
attempt separ gener busi ultim suspend beyond deal
activ bolt-on natur sever compani focus de-lever balanc sheet
given still rel high debt level expect major coverag acquir
instead think could look divest asset except view could
larg late-stag deal bull point larg de-lever transact separ
bhc forese near-term outcom
downgrad share overweight equal weight revis price target
prior base deal term cash share
posit stock sinc acquisit announc believ stock would
continu work investor got comfort likelihood acquisit close
expect occur base revis price target see approxim potenti
upsid stock qualifi overweight rate
could wrong thesi rate could derail compet higher bid
push deal close factor lead walk away deal oner
divestitur etc former stage believ anoth bidder arriv given
length time sinc merger announc latter review
remain key necessari requir deal close
 ftc approv agn/abbv acknowledg receipt request addit inform
documentari materi second request feder trade commiss updat
limit ftc approv industri meet sf month ceo gonzalez said
continu expect transact close first quarter
regulatori divestitur agn/abbv announc would divest brazikumab zenpep asset
irrespect whether divestitur requir regul faq document
post websit divestitur yet occur manag indic
earn robust divestitur process on-going right sever interest parti beyond
divestitur possibl ftc could come back request addit asset divest though
clear visibl ftc requir
ex-u regulatori approv european commiss approv transact subject
condit condit approv subject divestitur brazikumab commiss
indic would compet abbv risankizumab note agn/abbv alreadi previous indic
would divest product
net believ transact close see limit upsid potenti stock
current level
one top idea like setup share driven solid growth
base busi highlight primaten mist roll-out competitor suppli issu
unappreci pipelin provid long-term growth tailwind includ resubmiss two recent product
crl spend begin declin percent sale driven top line growth
catalyst-rich outlook underleverag balanc sheet longer term premier gx contract
china busi could meaning contributor price target base dcf unchang vs
prior assum termin ebitda multipl discount rate
base busi perform well believ execut well base busi highlight
growth potenti primaten mist roll-out sale primaten mist acceler
launch novemb primaten mist sale came
product contain cfc propel believ could product
prior peak sale signific near-term growth driver recent industri
meet note tv ad campaign began juli weekli same-stor sale
increas first week juli last week novemb competitor suppli issu
sever key product help near term well
growth pipelin underappreci stock sold earn compani
report two crl epinephrin vial complex inject cycl review former
alreadi resubmit gdufa date januari latter expect resubmit januari
well recent crl disappoint continu like strength
submit nda insulin program insulin program farther recent fda
draft guidanc clinic immunogen consider biosimilar interchang insulin
product look encourag file dmf forteo teriparatid could
meaning opportun year global sale approxim line
consensu well year inform view
catalyst-rich setup next month favor view could
sever pipelin approv epinephrin approv could launch
potenti market opportun longer term view premier gx contract china
busi meaning opportun well
balanc sheet underleverag rel cheap valuat net cash balanc sheet
valuat ev/sal view cheap rel growth outlook longer
term could also execut busi develop opportun
met manag recent industri meet sf overal walk away
increas confid stori believ compani execut well near-term longer
term prospect recent note
could wrong
primaten mist launch slower current model
addit setback pipelin much valu dcf pipelin focus
technic challeng higher margin gener increment crl possibl risk
chang analyst took fresh look bhc recent met senior manag
headquart base work upgrad bhc share equal weight underweight
rais price target per dcf valuat bhc attempt transit legaci valeant
issu loe expir acceler revenue/ebitda de-lever stori posit
organ growth l/intern total revenu remain solid low mid-singl
digit launch lumifi sihi daili launch help also believ
addit trulanc good fit salix salesforc earli script data look promis
bhc less expos gener opioid durabl portfolio asset
believ rel basi sourc fund group bhc also success push
debt matur favor rate howev balanc sever headwind
settlement stock drop suit repres full year push de-lever stori
xifaxan growth like slow commun street feedback
patent consult suggest risk earlier loe teva current settlement
model ebitda growth flattish driven apriso glumetza lotemax launch/r
invest ye product grow sever expect net
believ fall short recent physician feedback survey ran duobrii mix
given headwind think share like range-bound near term
support equal weight rate price target prior base dcf valuat
discount rate termin multipl chang valuat driven higher termin
multipl vs prior lower discount rate vs prior rais forecast
 l/ growth continu revenu shown
consist growth past sever quarter estim print organ growth
organ growth compani defin chang period-over-period basi revenu constant
currenc basi applic exclud impact acquisit divestitur discontinu
shown organ growth averag past quarter recent
driven solid growth global vision success lumifi launch
doubt lumifi solid launch bhc question larg product
octob bhc indic lumifi achiev weekli share revenu
bhc spoken addit line extens manag believ share
categori grow well all-in estim lumifi revenu
rest signific recal bhc guid billion annual peak total
revenu end signific product walk product
net think outlook mix better other believ billion sale
may optimist also includ physician survey duobrii
lumifi estim sale
relistor last januari bhc rais wac price relistor accord pricerx
wac price increas yoy script trend look posit
increas yoy compar yoy increas though softer past sever
week model sale
sihi daili launch expect believ street expect posit
launch manag recent call us driver growth current estim
sale
vyzulta uptak vyzulta disappoint sinc launch decemb
believ sale disclos outsid top product disclosur
note script look much better past sever week script look
yoy estim vyzulta sale
siliq siliq uptak well expect sale ytd
model sale bhc recent indic us continu optimist
regard long-term prospect siliq acknowledg launch slower
bryhali/duobrii tbd bryhali duobrii launch novemb june
respect bhc turn coupon drive uptak duobrii call ceo papa
indic duobrii payer coverag target access next summer goal
reimburs improv coupon diminish script trend bryhali
duobrii look weaken recent week estim total sale duobrii
bryhali
exhibit weekli script bryhali duobrii
given high expect duobrii launch ran survey dermatologist locat
 treat patient per month plaqu psoriasi familiar bhc bryhali
duobrii product overal physician seem satisfi product cost seem
issu bhc address via coupon qualit comment
exhibit prescrib duobrii would best character patient feedback
altern therapi thu far prescrib duobrii pleas select option
exhibit would character biggest impedi usag duobrii
qualit answer question includ follow
even close effect biolog
expens
mani insur plan signific cost patient inexperi product
patient prefer biolog topic
insur brand product unless patient fail gener therefor
difficult get brand product patient late
formulari
tough treat larg bodi area
satisfiedsatisfiedi yet prescrib duobriidissatisfiedextrem efficacyotherlack reimbursementcost specialti pharmaceut
exhibit bausch health start coupon process lower cost initi duobrii
impact prescrib behavior
exhibit key limit duobrii opinion think overal
increasesmoder increaseno impactphysician commentswork fine better limit psoriasi main issu cost get approv isnt super easi otherwis work wellth limit lack good head head data vs standard comparitor know worth fight get iti think ok product revolutionari effect irrit bc tazorachard get paid health insur planlimit -- effect biolog product hard get cover hinder prescrib elegantli formul patient irrit howev sometim cost access issu pose signific problem patient receiv treatment price point much paperwork effort topicaleasi get biolog duobrii challeng get coverag staff help pa coverageless efficacyth product one effect topic nowher close efficaci biolog overal topic product though prefer vitamin analogu sterod fix dose combo therapycosteffect product- limit attitud patientsadjunct biologicsit basic topic steroid retinoid probabl add littl efficaci retsrict use local psoriasi patient biolog residu diseas opinion duobrii similar efficaci topic steroid therefor difficult justifi ad cost product much efficaci gener outlook
exhibit expect prescrib bryhali indic mild moder psoriasi duobrii
patient
legaci stock drop litig resolv set de-lever stori back bhc
report net debt ttm net leverag net debt divid adj ebitda bausch
resolv stock drop litig approxim year expect fund
recent debt rais compani announc rais fund litig refinanc
senior note due understand push near-term matur
attract rate effect add debt push de-lever stori view
estim bhc end approxim debt net leverag
bull point sotp argument bhc share separ attract eye care
busi near term believ could prove challeng given debt level absent larg
xifaxan growth slow patent consult see risk patent xifaxan
grew yoy driven volum net price rebat proactiv step
taken improv gross net project bhc indic call variou public forum
benefit gtn repeat therefor growth slow low doubl digit
volum coupl hundr basi point net price model assum growth
iqvia script histor track report volum reason well increas
yoy vs ytd script weaker
likelysomewhat likelynot specialti pharmaceut
septemb bausch receiv notic sandoz file anda xifaxan tablet bausch
file suit sandoz trigger stay approv anda promin patent
consult review patent full detail shown net patent consult believ
patent portfolio strong weaker like fail
preclud entri start januari view expect gener entri
januari high probabl assign non-trivi risk gener entri
given background patent law reli part
expertis highlight risk stori note bausch current conduct trial
rifaximin acut ohe interim analysi bear monitor could potenti
extend durabl patent beyond patent consult current evalu
version xifaxan approv fda dosag approv
travel diarrhea dosag approv hepat encephalopathi ib
diarrhea focu dosag main version econom
current two challeng pend form
earli teva file anda dosag form salix su respons
case settl septemb public record contain almost help inform
howev case stay start may teva request teva need time
address concern fda rais respect bioequival propos
 recent septemb second challeng file time sandoz sandoz
anda seek fda approv one indic treatment ib diarrhea adult
respons salix/bausch file suit alleg infring patent
inform yet schedul case know automat
stay preclud fda approv least march also know district
court process presum take roughli long appeal would add even
time like anoth year clock
current orang book list xifaxan includ patent expir thu remain
relev patent consult break four categori patent cover
polymorph form patent relev ib patent relev travel diarrhea patent
relev hepat encephalopathi
accord patent consult big challeng salix face tri protect xifaxan
xifaxan polymorph rifaximin antibiot longer subject patent protect
inventor mani patent claim first realiz certain
condit specif certain time temperatur crystal dri step
carri particular polymorph produc compani thu draft patent
character time temperatur condit describ result pharmaceut compound
possibl salix would prefer patent rifaximin opinion
howev possibl salix settl approach identifi
polymorph patent method produc either purifi version
pharmaceut compound made twelv orang book patent fit
categori assert sandoz
normal patent consult would lump patent togeth singl discuss
truth almost imposs meaning distinguish patent one anoth
publicli known exactli concentr type polymorph import
xifaxan first place instanc earli patent expir newest one
persist might new patent enough stop entri cover essenti
concentr relev xifaxan polymorph might gener compani could enter
worri final detail polymorph good enough simpli
way know patent-by-pat basi issu play
public inform exactli polymorph go fda-approv drug also dont
know gener drug made use differ polymorph entir
state patent lawyer often suspici polymorph patent must sandoz
believ either work around polymorph see invalid patent
litig like invalid argument could follow
one possibl valid challeng patent could say even though one
knew time polymorph sure exist inventor identifi
true would set argument call inher anticip legal
doctrin bar someon patent someth fact exist even one knew
exist patent consult think argument success howev
salix patent go great detail precis concentr polymorph
simpli claim exist polymorph abstract put differ salix
essenc claim ownership purifi polymorph typic good answer
inher anticip concern intuit ye world might
polymorph form invent specif particular concentr
polymorph produc
 second possibl challeng would say surpris polymorph exist
obviou someon would ultim take next step character
howev salix/bausch convinc patent offic issu one two
separ patent basic set polymorph concept like consid
strong evid mani detail obviou
 third possibl approach sandoz one patent consult suspect like
succeed would use earlier-expir patent evid later-expir patent
obviou seven polymorph patent expir like much
stronger five polymorph patent expir file
relev patent prior art later patent
sandoz thu like primarili target later patent case
addit polymorph patent salix hold number patent target specif use
rifaximin polymorph includ patent go approv indic ib
travel diarrhea start ib indic disput sandoz
ib two patent left orang book mani seven
earlier point time miss patent expir remain patent would last
respect
 expir patent reason strong fda approv xifaxan ib
fda made clear time exact mechan action xifaxan
treatment ibs-d known thought relat chang bacteri content
gastrointestin tract even time approv neither fda salix fulli
understood xifaxan work clinic evid might impli
patent relat idea use xifaxan treat ibs-d non-obvi first
 remain patent howev look vulner patent consult seem
obviou light earlier-fil now-expir patent patent instanc add
detail clinic efficaci longev treatment strike kind
inform anyon skill art would readili develop origin idea
use xifaxan ib suggest patent better still puzzl
patent specif polymorph use seem obviou
someon skill art alreadi knew rifaximin help ib patient also
knew rifaximin sort polymorph
import patent seem like bar competit even valid
patent claim method patient given rifaximin day
yet continu experi relief roughli week drug label contrast
suggest day stipul long benefici impact last
thu would hard argu gener label infring patent
travel diarrhea meanwhil three patent three seem appli
instanc patient travel diarrhea also risk patent
face last juli patent consult reason doubt
non-obvi time file key patent featur high-level idea
rifaximin might help patient specif understand condit
rifaximin safe state problem patent label xifaxan
close overlap patent claim instanc label refer travel diarrhea
specif refer risk develop also suffer travel diarrhea thu
patent consult believ gener label need infring patent
patent expir patent broadli cover use
rifaximin treatment includ origin treatment effort keep remiss
noth patent document caus patent consult doubt would
defens litig howev patent suffici align label
instanc patent focu idea patient continu take drug month
label say noth need month treatment patent fail
reason instanc character expect chang patient
symptom use languag label
summari bausch patent polymorph rifaximin key question whether
polymorph repres patent-elig invent instead obviou given relationship
rifaximin polymorph form essenti work drug earliest
patent expir june latest import enough would last
septemb patent consult suspect later patent vulner
bausch three patent specif relat travel diarrhea combin hepat
encephalopathi expir juli patent consult think work
 bausch patent target hepat encephalopathi isol expir
patent consult think work around
 bausch two unexpir patent relev ib patent consult skeptic
two would surviv challeng longest-last one particularli weak
easi work around
thu patent consult think patent portfolio reason strong
middl polymorph patent expir portfolio
increasingli vulner last polymorph patent expir
portfolio seem extrem weak
could wrong
better expect guidanc ebitda growth street
signific sale meet exceed bhc target
bhc abl consumm de-lever transact sotp becom relev
sandoz challeng xifaxan settl similar term teva
differenti invest opportun spec pharma view good long-term revenu
visibl solid ebitda growth cash flow sector full uncertainti biodefens busi
year contract revenu anthrax franchis attract pipelin opportun
posit continu consolid biodefens sector well expand intern
target impli ebitda growth compound-annual-growth-rate recent issu guidanc look conserv us
competit narcan concern long term patent consult review teva challeng
favor script trend still look fine price target unchang vs prior support
dcf assum termin ebitda multipl discount rate
near-term organ growth attract like growth near term anthrax franchis
narcan co-rx legisl recent narcan script continu trend right direct though
drop week like setup beat year contract revenu
next sever year signific posit combin low-single-digit price escal
govern model assum top-line growth exclud bolt-on
believ margin expand
attract pipelin opportun sever biodefens pipelin asset look like attract
long-term candid includ chikungunya vaccin could
opportun season influenza
long-term target look achiev investor day novemb provid
year target revenu adj ebitda margin part revenu
target disclos assum organ growth mid upper singl digit rang
includ meaning revenu product develop today manag point
base case split organ growth note scenario get
sole organ growth view would like requir nonetheless midpoint
ebitda margin guidanc impli near doubl ebitda year compound-annual-growth-rate
view attract given contract visibl lack headwind drug price opioid etc
believ particularli favor also believ busi underappreci
narcan competit concern long term patent consult review teva case
acquisit adapt pharma controversi view may taken account
increas competit environ would disclos narcan revenu assumpt
long-term target indic assum brand competit
adapt current midst abbrevi new drug applic anda litig
teva regard respect anda gener version narcan nasal spray
ebs/adapt file complaint octob claim infring result
stay impos march regard teva litig adapt time receiv
notic septemb teva file anda seek approv gener version narcan
nasal spray expir patent teva claim infring patent
other list narcan teva also claim patent invalid unenforc notabl teva
gain fda approv gener april launch risk stay expir
april though think unlik stage speak understand
compani still wait date close argument
given overhang case promin patent consult review patent
case full detail shown net adapt strong patent protect cover specif
formul weaker still help patent protect broader idea administ
dose naloxon hydrochlorid via single-nostril nasal deliveri either type
patent would protect drug
narcan nasal spray deliv dose naloxon hydrochlorid directli singl nostril
product compet altern harder use includ product must prepar
prior use product deliv use inject spray also uniqu
use initi dose approach typic use first permit addit
dose need
adapt assert five patent relev narcan part patent famili
mean tie back initi patent file patent number
expir march
litig court teva
patent offic institut ipr three five patent patent
ipr type hear patent offic reconsid whether patent fact
rightli grant anyon ask patent offic institut ipr patent offic
institut instanc suffici evid suggest patent might
wrongli grant three patent patent offic view
enough evid warrant second look three consid anew
process lot like court hear except take place within period rather
drag court case often like court decis ipr decis
 made patent offic think three patent might wrongli
grant patent broadli assert right devic formul capabl deliv
naloxon hydrochlorid long formul includ certain amount
preserv stabil agent acid yet turn prior art refer
broadli suggest idea use nasal deliveri naloxon hydrochlorid
suggest broad rang possibl strength includ patent dose patent offic
thu institut ipr proceed argu overlap rang claim
composit disclos prior art creat presumpt obvious
 adapt might yet convinc patent offic patent properli issu adept
two main argument first prior art meaning teach ye prior art
document identifi rang larg enough includ adapt point
document call question moreov adapt also help real-world
evid support argument includ fact teva intern team express
surpris relev scientist found adapt nasal formul use
rather second adapt point real-world evid show
practic matter concept fact non-obvi exampl evid
expert skeptic nasal deliveri would yield suffici blood absorpt
evid demand product high impli real
world obviou teva lawyer say
overal adapt like prevail ipr issu close plan
get inform roughli june transcript avail actual ipr
hear final decis come august septemb
import note patent offic declin institut ipr proceed two
patent adapt assert relev narcan patent
patent offic thought patent strong claim one detail
specif requir use preserv benzalkonium chlorid adapt first drug
compani use preserv prior art seem question whether
preserv safe use intranas naloxon formul exampl
prior art refer document test done formul refer
explicitli discourag use benzalkonium chlorid theori particular
preserv caus naloxon degrad
 patent offic understand found evid persuas character
teach away turn patent insight put differ patent
offic took posit obviou use particular preserv quit
opposit skill art would known data suggest
 summari focu ipr issu argument play
patent litig specif litig teva well way court
alreadi heard evid court wait post-trial brief parti
court adapt argu detail formul patent one focu preserv
valid note prior art refer discourag use preserv
context teva respons argu someon skill art would discount
refer use much preserv definit anyon would
use practic patent consult view weak respons prior art
intent use much preserv purpos relev experi
test degrad sure test larg amount preserv use
whole point test reach conclus safeti use even smaller amount
adapt also present strong case favor broader patent focus real-world
evid note thu adapt introduc evid skill art
skeptic dose adapt abl show easy-to-us devic
warmli receiv market moreov patent consult sens testimoni
prior art document broadli suggest rang includ
realli strong sens would work specif also thought
sever teva wit took posit hurt credibl one expert
exampl argu nasal deliveri easier use needle-bas
ipr three patent move forward toward decis august septemb
 case teva wait post-trial brief like get decis
judg earli
 transcript ipr hear avail roughli june
overal patent consult believ adapt formul patent like
surviv think broader patent closer call nevertheless like
surviv
beyond teva candid develop could enter market
come year
adami zimhi naloxon auto-injector candid receiv fda novemb
amphastar intranas naloxon plan re-fil nda believ could
meaning competit threat narcan approv
hikma recent purchas naloxon nasal spray candid insi therapeut ceo
sigurdur oli olafsson state compani last earn call naloxon product
review much along think realli know exact statu
develop excit opportun feel still think quit time
product come market
work next-gener pipelin candid narcan includ naloxon multi-dos nasal
spray call naloxon pre-fil syring candid call program earli
could wrong
teva win narcan case competit intensifi sooner current expect
case multipl would like contract sure agre competit come believ
near term narcan revenu contribut continu posit
approxim half growth get revenu target includ
possibl larger value-destruct transact
key product jeuveau competit data aesthet treatment area pois grow
robustli next decad addit recent complet capit rais remov key
overhang howev rate driven fact still earli launch see
develop clariti itc case get construct stock note
short interest approxim outstand float
januari announc preliminari sale consensu
estim adjust model midpoint also assum
conserv launch outer year forecast price target revis prior
assum discount rate termin ebitda multipl
jeuveau progress date encourag like progress make believ sale
impress earli launch product annual sale think
exit quarter suggest run rate sale light consensu
estim look achiev note season light though could prove
non-issu given product launch
outer year estim look high us consensu estim call sale
consensu believ may take longer attain
level share given difficulti launch sidelin watch
litig overhang continu month background januari allergan partner
medytox file complaint daewoong intern trade commiss itc
stipul jeuveau manufactur base misappropri trade secret medytox
therefor import jeuveau unfair act itc matter entitl matter certain
botulinum toxin product itc complaint complaint accord
advers rule itc either us daewoong could result imposit exclus
order would bar import jeuveau unit state ceas desist order would
bar sale market jeuveau within unit state itc administr law judg
assign case david shaw per itc websit hold evidentiari hear feb
per itc alj make initi determin violat section
unfair import subject review itc initi determin due june final
determin due octob
addit face similar case brought medytox superior court state
california view overhang next month pontif
merit case rather see risk non-zero chanc litig
daewoong face neg rule view stock unlik work overhang
remov
could wrong
medytox litig goe evolus/daewoong favor overhang remov
jeuveau penetr sale ramp faster current model
continu posit potenti zilretta treatment oa pain believ could
potenti product longer term like penetr stori oa knee pain
encourag ancillari indic shoulder oa adhes capsul frozen shoulder
flexion penetr stori still earli inning sale momentum acceler recent
label revis like flattish believ guidanc conserv expect
continu beat street expect price target unchang vs prior deriv
dcf valuat assum termin ebitda multipl discount rate
sale momentum continu expect recent sale momentum zilretta continu
potenti acceler driven posit physician/pati feedback j-code place volume-bas
rebat program recent approv label revis gross-to-net disclos
earn call tick volume-bas rebat program initi howev
off-set robust volum growth believ good trade-off
exhibit zilretta sale unit growth
see collaps price derail thesi continu set conserv
expect posit stock earn beat number come consensu
current sale vs begin annual preliminari
sale annual nearli run-rat growth top
seem reason us near-term top line beat drive stock higher near-term view
label chang perfect best-cas scenario help penetr decemb
announc fda approv snda updat product label zilretta allow
remov languag state zilretta intend repeat administr
label state efficaci safeti repeat administr zilretta
demonstr revis label avail label chang perfect believ
best-cas scenario due potenti reimburs challeng repeat use inclus safeti
data trial plu net net drive increment sale growth recent
physician survey conduct point major physician indic remov lou languag would
impact prescrib behavior
exhibit flexion ultim success remov limit use lou languag
zilretta label state zilretta intend repeat administr remov
languag impact prescrib behavior zilretta
ex-u partnership agreement possibl longer term near-term focu
compani believ could execut partnership zilretta outsid
could wrong
sale miss street expect
oper loss financ risk
data shoulder oa adhes capsul studi unfavor
label chang success improv reimburs
continu like stori driven solid growth look linzess steadi
improv price profit post-spin better expect like
chang ex-u agreement believ capit alloc could focu given
improv profit ironwood two import readout year pipelin could
posit catalyst data abdomin pain data persist gerd
announc januari resolv patent litig regard sandoz anda
gener version linzess ironwood allergan expect grant sandoz licens market
mcg mcg gener version linzess begin februari
consist previou settlement patent case teva still on-going trial date
januari postpon continu settlement negoti
continu believ share under-valued price target base dcf valuat
linzess growth trend well rx demand linzess capsul yoy
manag highlight linzess becam prescrib ibsc/cic treatment driven
withdraw prescript miralax dtc campaign refresh consum materi per iqvia data
linzess trx post appear track line trend despit recent weak
price headwind appear moder manag kept guidanc mid- high-
single-digit price eros commentari call point improv
environ impact payor consolid repeat end decemb
linzess weekli share moder ytd share gain motegr takeda
trulanc bausch gener expect enter irwd/agn recent settl
sandoz teva anda case also postpon respect parti continu settlement
recent industri meet month ironwood indic expect mid-singl digit net sale
growth stabl net price consist expect also highlight launch
consum campaign discuss multipl abdomin symptom associ ibs-c
addit overal abdomin symptom data ad linzess label
profit improv focu shift capit alloc ex spin cyclerion chang ex-
 asset profit profil ironwood significantli improv guid
adj ebitda grow solid gener
view moder neg price headwind focu shift capit alloc activist sarissa
capit remain larg sharehold partnership gerd asset follow potenti posit
data may valuabl option
catalyst upcom pipelin asset ironwood two signific pipelin catalyst
start top-line data candid treat abdomin pain associ
ibs-d addit plan announc data trial candid
treat persist gerd
could wrong
lack product diversif competitor takeda bausch could take share linzess
unfavor readout two pipelin asset mid
price headwind moder potenti worsen
continu like share maintain overweight rate thesi predic
follow near term xyrem growth continu solid driven low- mid-single-digit
volum growth net price contribut pipelin underappreci view includ
lower sodium xyrem approv asparaginas think sodium oxyb
franchis durabl market may appreci given potenti launch give
year convert patient first gener hit top line data lurbinectein also
expect could launch acceler approv may potenti execut
larg commerci deal diversifi mix xyrem ahead gener entri
attract profil provid flexibl capac potenti deal stock rel cheap
turn discount brand peer coverag tweak price target prior
base dcf valuat termin multipl discount rate slightli higher xyrem forecast
xyrem growth look appeal expect recent xyrem sale momentum continu
consensu yoy driven low-single-digit volum growth
higher net price note accord pricerx januari xyrem wac price increas
rebates/discount also consensu total revenu ebitda see
set conserv guidanc beat year
expect competit threat wakix avadel harmoni bioscienc receiv
fda approv august wakix potenti competitor xyrem howev label narrow
expect ed like instead compet sunosi believ expect also
low avadel program nightli xyrem equival expect read top
line data
pipelin underappreci view like revenu opportun jzp-
expect approv posit potenti convers xyrem jzp-
recombin erwinia asparaginas pivot read-out potenti new pbl contract
would receiv posit view base discuss manag believ
would regulatori issu execut pbl contract
late-stag busi develop possibl catalyst gener entri approach
think time critic could year execut late-stag commerci deal net
leverag low ttm ebitda meaning capac
cash undrawn revolv could potenti borrow beyond ceo bruce cozadd indic
open deal recent confer diversif xyrem via larg late-stag asset
would posit catalyst stock view
stock cheap view current trade ebitda estim turn
discount brand peer coverag addit estim
equat double-digit yield like catalyst heavi natur next month potenti
drive stock higher see catalyst calendar
could wrong
top line data avadel nightli sodium oxyb could better data
current expect repres risk xyrem
convers difficult current expect gener entri
xyrem
neg data pivot trial
busi develop transpir diversifi mix xyrem
believ karuna repres compel invest opportun lead product karxt
potenti revolution treatment multipl indic includ psychosi
schizophrenia alzheim diseas repres multi-billion dollar address market
karuna pipelin in-a-product approach allow multipl approv opportun indic
schizophrenia pain view schizophrenia psychosi opportun alon support
addit upsid potenti stock dementia relat psychosi opportun model
exclud addit indic schizophrenia cognitive/neg symptom pain like risk-
reward stock see sever signific catalyst valu creation next month
price target prior deriv dcf valuat rais number base
higher probabl success schizophrenia psychosi vs prior gain comfort
trial design phase studi
under-valued base schizophrenia opportun alon karuna data schizophrenia
psychosi indic panss reduct vs approv anti-psychot coupl toler profil
includ tradit antipsychot side effect show reduct
baselin vs placebo compar averag reduct antipsychot trial approv
littl reduct karuna replic larger trial believ karuna could
approv drug antipsychot market sever drug sale
abilifi zyprexa etc base feedback receiv physician spoken
blockbust sale drug despit modest efficaci signific toler issu
patient switch everi month estim global peak sale risk-adjust
base po
posit read-through dementia relat psychosi potenti indic believ
schizophrenia result posit read-through favor data dementia relat psychosi
readout estim dementia relat psychosi global peak sale
risk adjust base po sever antipsychot black box warn still use
physician addit read-through posit symptom domain schizophrenia
includ model
sever signific catalyst next month end meet fda
schizophrenia-psychosi inform studi design recent meet
karuna manag give us increas confid data believ somewhat de-
risk top line data pain dementia relat psychosi initi
studi schizophrenia psychosi year-end
suffici near term end karuna report cash short-term invest
per prospectu indic net proce secondari offer
approxim believ could end year cash believ give
compani runway nda submiss schizophrenia psychosi includ two studi given
breadth data lilli xanomelin karxt result think one success studi may
suffici
trial design one key debat compani replic result
schizophrenia psychosi larger studi understand trial design larger
similar read-out dose endpoint
studi larger term site patient in-pati given similar
studi smaller size studi previous envis previous indic would
larger believ abl replic result note
improv would necessari approv
could wrong
stock signific increas valuat market digest secondari offer
given catalyst back-half weight possibl stock may tread water short
potenti approv launch still sever year away schizophrenia psychosi
increas competit intra-cellular other sector
lock-up expir decemb
maintain equal weight rate share compani face number risk
uncertainti includ payor headwind mnk largest product acthar new competit
product inomax ofirmev signific balanc sheet risk on-going opioid litig
suit upcom april debt matur recent debt exchang push april
debt still come due posit continu gener solid
estim opioid could come
favor market current envis addit still secur debt capac
could access new securit facil given limit visibl structur either
agreement decis due august still delay sidelin
stock strong recent potenti opioid settlement opioid
defend well possibl structur settlement past five trade session
potenti settlement key march ny opioid case vs
note float short
rais price target previous base dcf valuat assum
termin multipl discount rate key chang valuat framework assum
lower liabil cms/opioid litig
difficult situat face numer balanc sheet risk includ signific debt
prior acquisit opioid litig lawsuit govern cms/hh divis
non-zero probabl bankruptci thu expect equiti volatil base
market assess win case structur less oner payment settlement
sure see merit bull case base sourc fund favor outcom
case market price howev miss recent move stock
visibl legal outcom correspondingli improv
current gross debt net leverag market valu
compani april debt matur report cash
estim produc debt matur addit
believ secur debt capac well capac securit facil
howev visibl resolut global settlement opioid limit decis
judg case due august still receiv financi penalti
case could rang preced case look bench
case understand judg continu evalu includ increment detail
provid past week corollari case opioid global settlement recent industri
meet sf ceo mark trudeau note continu negoti plaintiff hope
fact resolut reach sooner later howev might imagin complex
negoti involv whole rang plaintiff differ object sheer volum
natur complex case creat fair bit uncertainti next key case suffolk
counti ny case start march hope global settlement ahead
court case settlement amount opioid structur deal difficult ascertain given
sheer number plaintiff
beyond headwind also face challeng lead product acthar
continu declin payor reimburs challeng addit understand praxair
market ginomax may face share loss come quarter
miss move stock past week given limit visibl mnk legal
headwind remain sidelin view market get clariti
could wrong
win case monetari penalti outcom
opioid rule favor spread mani year prevent bankruptci
two preced factor abl refin april debt
praxair adopt inomax gener take longer current anticip
believ mediwound repres compel invest opportun product view
potenti revolution treatment burn chronic wound approv stock
under-perform sinc decis partner nexobrid believ mani investor
expect sale still approv escharex opportun licens deal offer
signific upsid potenti note neither product approv share carri
signific risk approv adopt price target unchang base dcf
nexobrid nexobrid drug candid eschar remov deep partial full thick burn
mdwd size market opportun north america commerci collabor
agreement receiv up-front due upon us bla approv
annual sale mileston bla submiss expect occur
potenti bla approv
escharex escharex candid debrid chronic/hard-to-h wound day topic
design outpati set mdwd current conduct adapt design studi multi-
center random control evalu safeti efficaci escharex debrid venou
leg ulcer studi enrol patient random either escharex gel vehicl non-surg
standard care studi interim assess reach patient enrol
treat mdwd expect year-end complet data avail
studi expect durat similar number patient
like solid balanc sheet cash debt barda fund use
guid declin particularli receiv
could wrong
lack near-term catalyst
illiquid stock
maintain equal weight rate share significantli under-perform
stock declin owe execut miscu poor manag on-going gener industri
challeng announc merger upjohn appear track stock screen
rel cheap stand-alon basi newco look entic think expens
synergi attain also redomicil delawar give investor right improv
corpor govern encourag see compani bring season execut
includ ian reed board howev given volume-bas procur plan china slower
expect ramp key launch stabil still challeng gener busi acknowledg
smaller piec pie lack visibl compani long-term revenu ebitda
outlook newco guidanc key stori view manag indic
come around close mid net sidelin see manag execut
improv price target unchang vs prior deriv dcf valuat assum
discount rate termin ebitda multipl
recent industri meet sf chairman robert couri note follow dispel reason
doubt extrem confid number back also remain extrem confid
number put today respons view mani investor fear
compani talk recent forecast newco ebitda
mani thing like new compani re-domicil delawar improv corpor
govern gener one-third compani vs prior former ceo board new
ceo expens synergi look attain attract profil dividend may also
attract new group investor sever biosimilar opportun current
launch plan launch near futur includ follow
herceptin launch dec
fulphila recent announc acceler expans manufactur capac
help sale ramp
avastin opportun us/europ announc earn call intend
submit us bla end year eu submiss
insulin aspart submit fda plan launch
insulin glargin process address fda concern malaysia facil expect
behind confid approv key march date
howev us key question execut track record miss street expect
given reset still might come closer close sidelin stock
could wrong
manag execut significantli improv new ceo michael goettler
uptak complex gener biosimilar launch faster anticip
newco guidanc favor rel street expect
synergi come better expect
believ osmotica offer good valu spec pharma gener portfolio like continu trend
lower view reflect current valuat stock declin recent
file seek offer share primari work capit gener
corpor purpos offer believ share time reflect valu
pipelin notabl treatment ptosi pdufa date juli
also discuss potenti partner rvl ex-u plan resubmit nda arbaclofen
portfolio mix chang may also supplement via busi develop opportun
road view price target unchang vs prior base dcf assum
termin multipl discount rate
could meaning believ osmt key pipelin asset treatment
acquir blepharoptosi droopi eyelid could signific opportun nda accept
pdufa date set juli model assum sale approxim
risk adjust safeti efficaci studi met primari endpoint
chang baselin lpft mild moder like risk-reward approv
also current evalu opportun partner drug ex-u
path re-fil arbaclofen nda march trial arbaclofen er treat ms spastic
fail due demonstr superior placebo measur cgic scale though superior
tnma scale due safeti issu believ path forward plan resubmit
nda
gener portfolio like continu challeng osmotica gener portfolio compos
primarili methlyphenid venlafaxin continu challeng view driven high
competit declin price believ reflect stock current compani
note like continu declin sourc cash flow rest busi
could wrong
gener portfolio take anoth step faster current model
arbaclofen receiv fda approv
rvl partnership discuss fail materi
osmotica sizeabl debt balanc approxim declin ebitda
base busi setback pipelin would amplifi
share re-rat past year investor optimist growth
prospect new ceo murray kessler sidelin miss move stock
look gain increment evid turnaround durabl current valuat
potenti larg call cash three tax disput continu
overhang near term temporarili stall spin sale rx price target deriv
dcf valuat assum termin multipl discount rate account
durabl faster turnaround new ceo murray kessler previous envis
note dcf framework includ npv tax liabil
valuat improv significantli sinc begin post reset ntm
ev/ebitda multipl expand attribut higher growth expect
recent disclosur commentari see turnaround ceo murray
